You are here: Home » News-ANI » National
Business Standard

Delhi HC sets aside Centre's ban on 344 drugs

ANI  |  New Delh [India] 

The High on Thursday agreed with pharmaceutical companies and set side the Centre's notification on banning of 344 fixed dose combination (FDC) drugs

It maybe recalled that pharmaceutical companies had challenged the Centre's notification in the high court.

In all, 454 petitions were filed by these companies before the high court,challenging the Centre's decision to ban 344 fixed dose combination (FDC) medicines, including well known brands like Corex cough syrup, Vicks Action 500 extra and D'Cold.

High Justice Rajiv Sahai Endlaw on June 2 had reserved the order after hearing regular arguments of companies like Pfizer, Glenmark, Procter and Gamble and Cipla, the Centre and some NGOs like All Drug Action Network (AIDAN) over a span of over two months, starting from March 14.

The had on March 14 stayed the Centre's March 10 ban on 344 drugs and this interim order was passed in each and every case filed before it thereafter.

During arguments, the drug companies had contended that the government has not properly implemented the powers under Section 26A (Power to Prohibit Manufacture of Drugs and Cosmetics in Public Interest) of Drugs and Cosmetics Act, under which the ban was ordered.

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

RECOMMENDED FOR YOU

Delhi HC sets aside Centre's ban on 344 drugs

The Delhi High Court on Thursday agreed with pharmaceutical companies and set side the Centre's notification on banning of 344 fixed dose combination (FDC) drugsIt maybe recalled that pharmaceutical companies had challenged the Centre's notification in the high court.In all, 454 petitions were filed by these companies before the high court,challenging the Centre's decision to ban 344 fixed dose combination (FDC) medicines, including well known brands like Corex cough syrup, Vicks Action 500 extra and D'Cold.Delhi High Court Justice Rajiv Sahai Endlaw on June 2 had reserved the order after hearing regular arguments of companies like Pfizer, Glenmark, Procter and Gamble and Cipla, the Centre and some NGOs like All India Drug Action Network (AIDAN) over a span of over two months, starting from March 14.The court had on March 14 stayed the Centre's March 10 ban on 344 FDC drugs and this interim order was passed in each and every case filed before it thereafter.During arguments, the drug ...

The High on Thursday agreed with pharmaceutical companies and set side the Centre's notification on banning of 344 fixed dose combination (FDC) drugs

It maybe recalled that pharmaceutical companies had challenged the Centre's notification in the high court.

In all, 454 petitions were filed by these companies before the high court,challenging the Centre's decision to ban 344 fixed dose combination (FDC) medicines, including well known brands like Corex cough syrup, Vicks Action 500 extra and D'Cold.

High Justice Rajiv Sahai Endlaw on June 2 had reserved the order after hearing regular arguments of companies like Pfizer, Glenmark, Procter and Gamble and Cipla, the Centre and some NGOs like All Drug Action Network (AIDAN) over a span of over two months, starting from March 14.

The had on March 14 stayed the Centre's March 10 ban on 344 drugs and this interim order was passed in each and every case filed before it thereafter.

During arguments, the drug companies had contended that the government has not properly implemented the powers under Section 26A (Power to Prohibit Manufacture of Drugs and Cosmetics in Public Interest) of Drugs and Cosmetics Act, under which the ban was ordered.

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

image
Business Standard
177 22

Delhi HC sets aside Centre's ban on 344 drugs

The High on Thursday agreed with pharmaceutical companies and set side the Centre's notification on banning of 344 fixed dose combination (FDC) drugs

It maybe recalled that pharmaceutical companies had challenged the Centre's notification in the high court.

In all, 454 petitions were filed by these companies before the high court,challenging the Centre's decision to ban 344 fixed dose combination (FDC) medicines, including well known brands like Corex cough syrup, Vicks Action 500 extra and D'Cold.

High Justice Rajiv Sahai Endlaw on June 2 had reserved the order after hearing regular arguments of companies like Pfizer, Glenmark, Procter and Gamble and Cipla, the Centre and some NGOs like All Drug Action Network (AIDAN) over a span of over two months, starting from March 14.

The had on March 14 stayed the Centre's March 10 ban on 344 drugs and this interim order was passed in each and every case filed before it thereafter.

During arguments, the drug companies had contended that the government has not properly implemented the powers under Section 26A (Power to Prohibit Manufacture of Drugs and Cosmetics in Public Interest) of Drugs and Cosmetics Act, under which the ban was ordered.

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

image
Business Standard
177 22

Upgrade To Premium Services

Welcome User

Business Standard is happy to inform you of the launch of "Business Standard Premium Services"

As a premium subscriber you get an across device unfettered access to a range of services which include:

  • Access Exclusive content - articles, features & opinion pieces
  • Weekly Industry/Genre specific newsletters - Choose multiple industries/genres
  • Access to 17 plus years of content archives
  • Set Stock price alerts for your portfolio and watch list and get them delivered to your e-mail box
  • End of day news alerts on 5 companies (via email)
  • NEW: Get seamless access to WSJ.com at a great price. No additional sign-up required.
 

Premium Services

In Partnership with

 

Dear Guest,

 

Welcome to the premium services of Business Standard brought to you courtesy FIS.
Kindly visit the Manage my subscription page to discover the benefits of this programme.

Enjoy Reading!
Team Business Standard